Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase

被引:21
作者
de Man, FHAF
de Beer, F
van der Laarse, A
Smelt, AHM
Leuven, JAG
Havekes, LM [1 ]
机构
[1] Univ Leiden Hosp, Dept Cardiol, NL-2300 RC Leiden, Netherlands
[2] Univ Leiden Hosp, Dept Internal Med, NL-2300 RC Leiden, Netherlands
[3] TNO, Gaubius Lab, NL-2301 CE Leiden, Netherlands
关键词
atherosclerosis; triglyceride; VLDL; metabolism; familial dysbetalipoproteinemia;
D O I
10.1016/S0021-9150(97)00218-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein lipase (LPL) is bound to heparan sulphate proteoglycans (HSPG) at the luminal surface of endothelium. It is the key enzyme involved in the hydrolysis of very low density lipoproteins (VLDL). Prior to lipolysis by LPL, the lipoproteins are considered to interact with vessel wall HSPG. Apolipoprotein (ape) E is thought to mediate this interaction thereby enhancing the stability of the lipoprotein-LPL complex. We hypothesize that apo E mutations may cause a diminished interaction of VLDL with HSPG leading to impaired lipolysis of VLDL by HSPG-bound LPL. In order to test this hypothesis, lipolysis experiments were performed using HSPG-bound LPL. The mean lipolysis rates of VLDL, isolated from the apo E2 (Lys(146) -->Gln) heterozygotes, apo E2 (Arg(158)-->Cys) homozygotes and apo E3-Leiden heterozygotes were 92.3 +/- 10.3 (ns), 77.3 +/- 4.2 (P < 0.05) and 76.7 +/- 10.0% (P < 0.05), respectively, of that of control VLDL (100.0 +/- 9.7%). No differences in lipolysis were observed between VLDL from controls and VLDL from the same patients if LPL in solution was used. Thus, compositional differences alone can not explain the differences in lipolysis rates observed with HSPG-bound LPL. In competition experiments, the binding efficiency to HSPG-LPL of VLDL from the apo E2 (Lys(146)-->Gln) heterozygotes, apo E2 (Arg(158)-->Cys) homozygotes and apo E3-Leiden heterozygotes was 63 (ns), 41 (P < 0.05) and 35% (P < 0.05), respectively of that of control VLDL (100%). We conclude that VLDL isolated from apo E2 homozygotes and apo E3-Leiden heterozygotes display decreased lipolysis by HSPG-bound LPL due to a defective binding of these lipoproteins to the HSPG-LPL complex. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码:255 / 262
页数:8
相关论文
共 33 条
[1]   THE LDL RECEPTOR RELATED PROTEIN, LRP, IS AN APOLIPOPROTEIN-E-BINDING PROTEIN [J].
BEISIEGEL, U ;
WEBER, W ;
IHRKE, G ;
HERZ, J ;
STANLEY, KK .
NATURE, 1989, 341 (6238) :162-164
[2]   METABOLISM OF VERY LOW-DENSITY LIPOPROTEIN PROTEINS .1. PRELIMINARY IN-VITRO AND IN-VIVO OBSERVATIONS [J].
BILHEIMER, DW ;
LEVY, RI ;
EISENBERG, S .
BIOCHIMICA ET BIOPHYSICA ACTA, 1972, 260 (02) :212-+
[3]  
CHAIT A, 1977, LANCET, V1, P1176
[4]   GENETIC-HETEROGENEITY OF APOLIPOPROTEIN-E AND ITS INFLUENCE ON PLASMA-LIPID AND LIPOPROTEIN LEVELS [J].
DEKNIJFF, P ;
VANDENMAAGDENBERG, AMJM ;
FRANTS, RR ;
HAVEKES, LM .
HUMAN MUTATION, 1994, 4 (03) :178-194
[5]   FAMILIAL DYSBETALIPOPROTEINEMIA ASSOCIATED WITH APOLIPOPROTEIN E3-LEIDEN IN AN EXTENDED MULTIGENERATION PEDIGREE [J].
DEKNIJFF, P ;
VANDENMAAGDENBERG, AMJM ;
STALENHOEF, AFH ;
LEUVEN, JAG ;
DEMACKER, PNM ;
KUYT, LP ;
FRANTS, RR ;
HAVEKES, LM .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (02) :643-655
[6]   VARIABLE EXPRESSION OF FAMILIAL DYSBETALIPOPROTEINEMIA IN APOLIPOPROTEIN E(ASTERISK)2(LYS146-]GLN) ALLELE CARRIERS [J].
DEKNIJFF, P ;
VANDENMAAGDENBERG, AMJM ;
BOOMSMA, DI ;
STALENHOEF, AFH ;
SMELT, AHM ;
KASTELEIN, JJP ;
MARAIS, AD ;
FRANTS, RR ;
HAVEKES, LM .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1252-1262
[7]  
Goldberg IJ, 1996, J LIPID RES, V37, P693
[8]  
HAVEKES LM, 1987, J LIPID RES, V28, P455
[9]   Lipoprotein lipase stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages [J].
Hendriks, WL ;
vanderBoom, H ;
vanVark, LC ;
Havekes, LM .
BIOCHEMICAL JOURNAL, 1996, 314 :563-568
[10]   Apolipoprotein El-Hammersmith (Lys146->Asn;Arg147->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia [J].
Hoffer, MJV ;
Niththyananthan, S ;
Naoumova, RP ;
Kibirige, MS ;
Frants, RR ;
Havekes, LM ;
Thompson, GR .
ATHEROSCLEROSIS, 1996, 124 (02) :183-189